Hearts are unable to repair themselves.
Following a heart attack or other cardiovascular injury, the heart cannot regenerate its weakened muscles, resulting in reduced blood-pumping capacity. While medications, including newer drugs for obesity, have been improving the management of heart failure symptoms, patients often face two primary options: a heart transplant or the implantation of a heart device.
However, a recent small study has shown promise with an innovative technique. Participants received patches of heart muscle engineered from induced pluripotent stem cells, which led to thickening of their re-muscularized heart walls, thereby enhancing pumping ability and slightly improving their quality of life. This biological ventricular assist tissue in a patch, known as BioVAT, is designed to serve as a transitional solution for patients awaiting either a heart transplant, which often involves long wait times, or the implantation of a left ventricular assist device (LVAD) in cases of end-stage heart failure. A larger trial is anticipated to identify the most suitable candidates for this treatment and to assess its long-term effectiveness.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
.

